{"Q": 1, "answer": "no", "rationale": "'better match' modifies 'match', not a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_2796", "batch_size": 200, "batch_pos": 190, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "No high-potency verb, potent metaphor, alert phrase, superlative + harm noun, or intensifier + harm noun found.", "method": "llm_batch", "batch_id": "batch_2_13712", "batch_size": 200, "batch_pos": 157, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_18640", "batch_size": 200, "batch_pos": 76, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_1472", "batch_size": 200, "batch_pos": 72, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports development/testing efforts, no explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_17880", "batch_size": 200, "batch_pos": 67, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain the 'minimiser + scale contrast' pattern.", "method": "llm_batch", "batch_id": "batch_6_14652", "batch_size": 200, "batch_pos": 16, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_12708", "batch_size": 200, "batch_pos": 192, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes ongoing development/testing ('are already developing or about to test sample human vaccines') as a precautionary measure, a capability/preparedness action, without explicit calming language.", "method": "llm_batch", "batch_id": "batch_8_14856", "batch_size": 200, "batch_pos": 155, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
